1
|
Nomura M, Tomita J, Itakura S, Todo H, Kodama N, Inoue Y. Study of the preparation, characterization, and solubility of lidocaine complexed with 5-sulfosalicylic acid dihydrate. Drug Dev Ind Pharm 2024:1-17. [PMID: 39030701 DOI: 10.1080/03639045.2024.2382396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2024] [Accepted: 07/16/2024] [Indexed: 07/21/2024]
Abstract
OBJECTIVE This study was to prepare solid dispersions of lidocaine (Lid) with 5-sulfosalicylic acid dihydrate (SSA) by freeze-drying (freeze-dried [FD] Lid/SSA = 1/1) and to evaluate their physical properties. METHODS Here, we evaluated the physicochemical properties and solubility of solid dispersions of lidocaine (Lid) and 5-sulfosalicylic acid dihydrate (SSA) prepared by freeze-drying (freeze-dried [FD] Lid/SSA = 1/1). RESULTS Differential scanning calorimetry measurements showed that after freeze-drying, the endothermic peak due to Lid melting, the dehydration peak, and the endothermic peak due to SSA melting disappeared. Powder X-ray diffraction results showed that the characteristic Lid and SSA peaks disappeared after freeze-drying, indicating a halo pattern. The near-infrared spectroscopy results suggested that Lid-derived -NH and -CH groups and the Lid-derived -OH and -CH groups from the SSA peak shifted and broadened after freeze-drying, suggesting their involvement in complex formation through Lid/SSA intermolecular interactions. Nuclear Overhauser effect spectroscopy-nuclear magnetic resonance (NMR) measurements showed a cross-peak due to the interaction between the Lid-derived -CH group and the SSA-derived -OH group, suggesting hydrogen bonding. Diffusion-ordered spectroscopy NMR measurements showed that the diffusion coefficients of Lid and SSA aggregated in FD Lid/SSA, suggesting a change in Lid dispersibility in the solvent owing to the formation of a complex with SSA. The solubility of FD Lid/SSA was approximately 88 mg/mL (∼20-fold higher than that of Lid). CONCLUSIONS These findings suggest that complex formation occurred in FD Lid/SSA; this enhanced the solubility of this dispersion.
Collapse
Affiliation(s)
- Manami Nomura
- Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| | - Junki Tomita
- Instrument Analysis Center, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Shoko Itakura
- Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Hiroaki Todo
- Laboratory of Pharmaceutics and Cosmetics, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Nao Kodama
- Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| | - Yutaka Inoue
- Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| |
Collapse
|
2
|
Uspenskaya EV, Kuzmina E, Quynh HTN, Komkova MA, Kazimova IV, Timofeev AA. Influence of Mechanical Loading on the Process of Tribochemical Action on Physicochemical and Biopharmaceutical Properties of Substances, Using Lacosamide as an Example: From Micronisation to Mechanical Activation. Pharmaceutics 2024; 16:798. [PMID: 38931919 PMCID: PMC11207894 DOI: 10.3390/pharmaceutics16060798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 06/05/2024] [Accepted: 06/11/2024] [Indexed: 06/28/2024] Open
Abstract
Many physical and chemical properties of solids, such as strength, plasticity, dispersibility, solubility and dissolution are determined by defects in the crystal structure. The aim of this work is to study in situ dynamic, dispersion, chemical, biological and surface properties of lacosamide powder after a complete cycle of mechanical loading by laser scattering, electron microscopy, FR-IR and biopharmaceutical approaches. The SLS method demonstrated the spontaneous tendency toward surface-energy reduction due to aggregation during micronisation. DLS analysis showed conformational changes of colloidal particles as supramolecular complexes depending on the loading time on the solid. SEM analysis demonstrated the conglomeration of needle-like lacosamide particles after 60 min of milling time and the transition to a glassy state with isotropy of properties by the end of the tribochemistry cycle. The following dynamic properties of lacosamide were established: elastic and plastic deformation boundaries, region of inhomogeneous deformation and fracture point. The ratio of dissolution-rate constants in water of samples before and after a full cycle of loading was 2.4. The lacosamide sample, which underwent a full cycle of mechanical loading, showed improved kinetics of API release via analysis of dissolution profiles in 0.1 M HCl medium. The observed activation-energy values of the cell-death biosensor process in aqueous solutions of the lacosamide samples before and after the complete tribochemical cycle were 207 kJmol-1 and 145 kJmol-1, respectively. The equilibrium time of dissolution and activation of cell-biosensor death corresponding to 20 min of mechanical loading on a solid was determined. The current study may have important practical significance for the transformation and management of the properties of drug substances in solid form and in solutions and for increasing the strength of drug matrices by pre-strain hardening via structural rearrangements during mechanical loading.
Collapse
Affiliation(s)
- Elena V. Uspenskaya
- Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia; (E.K.); (H.T.N.Q.); (M.A.K.); (I.V.K.)
| | - Ekaterina Kuzmina
- Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia; (E.K.); (H.T.N.Q.); (M.A.K.); (I.V.K.)
| | - Hoang Thi Ngoc Quynh
- Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia; (E.K.); (H.T.N.Q.); (M.A.K.); (I.V.K.)
| | - Maria A. Komkova
- Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia; (E.K.); (H.T.N.Q.); (M.A.K.); (I.V.K.)
| | - Ilaha V. Kazimova
- Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia; (E.K.); (H.T.N.Q.); (M.A.K.); (I.V.K.)
| | - Aleksey A. Timofeev
- Scientific and Educational Resource Centre “Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis”, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia;
| |
Collapse
|
3
|
Figueiredo J, Mendes M, Pais A, Sousa J, Vitorino C. Microfluidics-on-a-chip for designing celecoxib-based amorphous solid dispersions: when the process shapes the product. Drug Deliv Transl Res 2024:10.1007/s13346-024-01633-7. [PMID: 38861140 DOI: 10.1007/s13346-024-01633-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2024] [Indexed: 06/12/2024]
Abstract
The fundamental idea underlying the use of amorphous solid dispersions (ASDs) is to make the most of the solubility advantage of the amorphous form of a drug. However, the drug stability becomes compromised due to the higher free energy and disorder of molecular packing in the amorphous phase, leading to crystallization. Polymers are used as a matrix to form a stable homogeneous amorphous system to overcome the stability concern. The present work aims to design ASD-based formulations under the umbrella of quality by design principles for improving oral drug bioavailability, using celecoxib (CXB) as a model drug. ASDs were prepared from selected polymers and tested both individually and in combinations, using various manufacturing techniques: high-shear homogenization, high-pressure homogenization, microfluidics-on-a-chip, and spray drying. The resulting dispersions were further optimized, resorting to a 32 full-factorial design, considering the drug:polymers ratio and the total solid content as variables. The formulated products were evaluated regarding analytical centrifugation and the influence of the different polymers on the intrinsic dissolution rate of the CXB-ASDs. Microfluidics-on-a-chip led to the amorphous status of the formulation. The in vitro evaluation demonstrated a remarkable 26-fold enhancement in the intrinsic dissolution rate, and the translation of this formulation into tablets as the final dosage form is consistent with the observed performance enhancement. These findings are supported by ex vivo assays, which exhibited a two-fold increase in permeability compared to pure CXB. This study tackles the bioavailability hurdles encountered with diverse active compounds, offering insights into the development of more effective drug delivery platforms.
Collapse
Affiliation(s)
- Joana Figueiredo
- Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal
| | - Maria Mendes
- Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, 3004-535, Coimbra, Portugal
| | - Alberto Pais
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, 3004-535, Coimbra, Portugal
| | - João Sousa
- Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, 3004-535, Coimbra, Portugal
| | - Carla Vitorino
- Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, 3004-535, Coimbra, Portugal.
| |
Collapse
|
4
|
Leśnikowski ZJ, Ekholm F, Hosmane NS, Kellert M, Matsuura E, Nakamura H, Olejniczak AB, Panza L, Rendina LM, Sauerwein WAG. Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)-Proposal for a Guide. Cells 2024; 13:798. [PMID: 38786022 PMCID: PMC11119693 DOI: 10.3390/cells13100798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/24/2024] [Accepted: 05/03/2024] [Indexed: 05/25/2024] Open
Abstract
Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized methods to be used in the early stages of boron carrier development in vitro. The selection of assays and corresponding methods is based on the practical experience of the authors and is certainly not exhaustive, but open to discussion. The proposed tests/characteristics: Solubility, lipophilicity, stability, cytotoxicity, and cellular uptake apply to both low molecular weight (up to 500 Da) and high molecular weight (5000 Da and more) boron carriers. However, the specific methods have been selected primarily for low molecular weight boron carriers; in the case of high molecular weight compounds, some of the methods may need to be adapted.
Collapse
Affiliation(s)
- Zbigniew J. Leśnikowski
- Laboratory of Medicinal Chemistry, Institute of Medical Biology PAS, Lodowa 106, 93-232 Lodz, Poland
| | - Filip Ekholm
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland;
| | - Narayan S. Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA;
| | - Martin Kellert
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany; (M.K.); (L.P.)
| | - Eiji Matsuura
- Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-0005, Japan;
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8501, Japan;
| | | | - Luigi Panza
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany; (M.K.); (L.P.)
- Dipartimento di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, L.go Donegani, 2/3-28100 Novara, Italy
| | - Louis M. Rendina
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia;
| | - Wolfgang A. G. Sauerwein
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany; (M.K.); (L.P.)
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany
| |
Collapse
|
5
|
Moon C, Sahakijpijarn S, Maier EY, Taft DR, Jara MO, Praphawatvet T, Manandhar R, Shetty N, Lubach J, Narang A, Nagapudi K, Williams RO. Inhaled JAK Inhibitor GDC-0214 Nanoaggregate Powder Exhibits Improved Pharmacokinetic Profile in Rats Compared to the Micronized Form: Benefits of Thin Film Freezing. Mol Pharm 2024; 21:564-580. [PMID: 38215042 DOI: 10.1021/acs.molpharmaceut.3c00719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2024]
Abstract
Asthma is a common chronic disease affecting the airways in the lungs. The receptors of allergic cytokines, including interleukin (IL)-4, IL-5, and IL-13, trigger the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, which involves the pathogenesis of asthma. GDC-0214 is a JAK inhibitor that was developed as a potent and selective target for the treatment of asthma, specifically targeting the lungs. While inhaled GDC-0214 is a promising novel treatment option against asthma, improvement is still needed to achieve increased potency of the powder formulation and a reduced number of capsules containing powder to be inhaled. In this study, high-potency amorphous powder formulations containing GDC-0214 nanoaggregates for dry powder inhalation were developed using particle engineering technology, thin film freezing (TFF). A high dose per capsule was successfully achieved by enhancing the solubility of GDC-0214 and powder conditioning. Lactose and/or leucine as excipients exhibited optimum stability and aerosolization of GDC-0214 nanoaggregates, and aerosolization of the dose was independent of air flow through the device between 2 and 6 kPa pressure drops. In the rat PK study, formulation F20, which contains 80% GDC-0214 and 20% lactose, resulted in the highest AUC0-24h in the lungs with the lowest AUC0-24h in the plasma that corresponds to a 4.8-fold higher ratio of the lung-to-plasma exposures compared to micronized crystalline GDC-0214 powder administered by dry powder inhalation. Therefore, GDC-0214 nanoaggregates produced by TFF provided an improved dry powder for inhalation that can lead to enhanced therapeutic efficacy with a lower risk of systemic toxicity.
Collapse
Affiliation(s)
- Chaeho Moon
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
| | - Sawittree Sahakijpijarn
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
- TFF Pharmaceuticals, Inc., Austin, Texas 78753, United States
| | - Esther Y Maier
- Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78723, United States
| | - David R Taft
- Division of Pharmaceutical Sciences, Long Island University, Brooklyn, New York 11201, United States
| | - Miguel O Jara
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
| | - Tuangrat Praphawatvet
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
| | | | - Nivedita Shetty
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Joseph Lubach
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Ajit Narang
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Karthik Nagapudi
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Robert O Williams
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
| |
Collapse
|
6
|
Raines K, Agarwal P, Augustijns P, Alayoubi A, Attia L, Bauer-Brandl A, Brandl M, Chatterjee P, Chen H, Yu YC, Coutant C, Coutinho AL, Curran D, Dressman J, Ericksen B, Falade L, Gao Y, Gao Z, Ghosh D, Ghosh T, Govada A, Gray E, Guo R, Hammell D, Hermans A, Jaini R, Li H, Mandula H, Men S, Milsmann J, Moldthan H, Moody R, Moseson DE, Müllertz A, Patel R, Paudel K, Reppas C, Savkur R, Schaefer K, Serajuddin A, Taylor LS, Valapil R, Wei K, Weitschies W, Yamashita S, Polli JE. Drug Dissolution in Oral Drug Absorption: Workshop Report. AAPS J 2023; 25:103. [PMID: 37936002 DOI: 10.1208/s12248-023-00865-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 10/02/2023] [Indexed: 11/09/2023] Open
Abstract
The in-person workshop "Drug Dissolution in Oral Drug Absorption" was held on May 23-24, 2023, in Baltimore, MD, USA. The workshop was organized into lectures and breakout sessions. Three common topics that were re-visited by various lecturers were amorphous solid dispersions (ASDs), dissolution/permeation interplay, and in vitro methods to predict in vivo biopharmaceutics performance and risk. Topics that repeatedly surfaced across breakout sessions were the following: (1) meaning and assessment of "dissolved drug," particularly of poorly water soluble drug in colloidal environments (e.g., fed conditions, ASDs); (2) potential limitations of a test that employs sink conditions for a poorly water soluble drug; (3) non-compendial methods (e.g., two-stage or multi-stage method, dissolution/permeation methods); (4) non-compendial conditions (e.g., apex vessels, non-sink conditions); and (5) potential benefit of having both a quality control method for batch release and a biopredictive/biorelevant method for biowaiver or bridging scenarios. An identified obstacle to non-compendial methods is the uncertainty of global regulatory acceptance of such methods.
Collapse
Affiliation(s)
- Kimberly Raines
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Payal Agarwal
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Patrick Augustijns
- Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, ON2 Herestraat 49-Box 921, 3000, Leuven, Belgium
| | - Alaadin Alayoubi
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Lucas Attia
- Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, Massachusetts, 02139, USA
| | | | - Martin Brandl
- University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark
| | - Parnali Chatterjee
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Hansong Chen
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Yuly Chiang Yu
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA
| | - Carrie Coutant
- Eli Lilly and Company, 893 Delaware St, Indianapolis, Indiana, 46225, USA
| | | | - David Curran
- GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania, 19046, USA
| | - Jennifer Dressman
- Fraunhofer Institute of Translational Pharmacology and Medicine, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany
| | - Bryan Ericksen
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Leah Falade
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Yi Gao
- AbbVie Inc, 1 North Waukegan Road, North Chicago, Illinois, 60064, USA
| | - Zongming Gao
- Food and Drug Administration, Center for Drug Evaluation and Research, St. Louis, Missouri, USA
| | - Debasis Ghosh
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Tapash Ghosh
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Anitha Govada
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Elizabeth Gray
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Ruiqiong Guo
- Takeda Pharmaceuticals, 650 E Kendall St, Cambridge, Massachusetts, 02142, USA
| | - Dana Hammell
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA
| | - Andre Hermans
- Merck & Co. Inc., 2025 E Scott Ave, Rahway, New Jersey, 07065, USA
| | - Rohit Jaini
- Pfizer Inc., 1 Portland St, Cambridge, Massachusetts, 02139, USA
| | - Hanlin Li
- Vertex Pharmaceuticals, 50 Northern Ave, Boston, Massachusetts, 02210, USA
| | - Haritha Mandula
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Shuaiqian Men
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA
| | - Johanna Milsmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400, Biberach an der Riss, Germany
| | - Huong Moldthan
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Rebecca Moody
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Dana E Moseson
- Pfizer Inc., 558 Eastern Point Rd., Groton, Connecticut, 06340, USA
| | - Anette Müllertz
- University of Copenhagen, Nørregade 10, 1165, København, Denmark
| | - Roshni Patel
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA
| | - Kalpana Paudel
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Christos Reppas
- National and Kapodistrian University of Athens, 157 72, Athens, Greece
| | - Rajesh Savkur
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | - Kerstin Schaefer
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400, Biberach an der Riss, Germany
| | - Abu Serajuddin
- Department of Pharmaceutical Sciences, St John's University, 8000 Utopia Parkway, Queens, New York, USA
| | - Lynne S Taylor
- Purdue University, 610 Purdue Mall, West Lafayette, Indiana, 47907, USA
| | - Rutu Valapil
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA
| | - Kevin Wei
- Food and Drug Administration, Center for Drug Evaluation and Research, White Oak, Maryland, USA
| | | | - Shinji Yamashita
- Ritsumeikan University, 56-1 Tojiin Kitamachi, Kita Ward, Kyoto, 603-8577, Japan
| | - James E Polli
- University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
| |
Collapse
|
7
|
Han J, Tang M, Yang Y, Sun W, Yue Z, Zhang Y, Zhu Y, Liu X, Wang J. Amorphous solid dispersions: Stability mechanism, design strategy and key production technique of hot melt extrusion. Int J Pharm 2023; 646:123490. [PMID: 37805146 DOI: 10.1016/j.ijpharm.2023.123490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 10/02/2023] [Accepted: 10/04/2023] [Indexed: 10/09/2023]
Abstract
Solid dispersion (SD) system has been used as an effective formulation strategy to increase in vitro and in vivo performances of poorly water-soluble drugs, such as solubility/dissolution, stability and bioavailability. This review provides a comprehensive SD classification and identifies the most popular amorphous solid dispersions (ASDs). Meanwhile, this review further puts forward the systematic design strategy of satisfactory ASDs in terms of drug properties, carrier selection, preparation methods and stabilization mechanisms. In addition, hot melt extrusion (HME) as the continuous manufacturing technique is described including the principle and structure of HME instrument, key process parameters and production application, in order to guide the scale-up of ASDs and develop more ASD products to the market in pharmaceutical industry.
Collapse
Affiliation(s)
- Jiawei Han
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China; Changzhou Pharmaceutical Factory Co., LTD, Changzhou 213018, PR China; College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, PR China
| | - Mengyuan Tang
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China
| | - Yang Yang
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China
| | - Wen Sun
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China
| | - Zhimin Yue
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China
| | - Yunran Zhang
- Changzhou Pharmaceutical Factory Co., LTD, Changzhou 213018, PR China
| | - Yijun Zhu
- Changzhou Pharmaceutical Factory Co., LTD, Changzhou 213018, PR China
| | - Xiaoqian Liu
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China.
| | - Jue Wang
- School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China; College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, PR China.
| |
Collapse
|
8
|
Moseson DE, Taylor LS. Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions. Mol Pharm 2023; 20:4802-4825. [PMID: 37699354 DOI: 10.1021/acs.molpharmaceut.3c00526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023]
Abstract
Does the performance of an amorphous solid dispersion rely on having 100% amorphous content? What specifications are appropriate for crystalline content within an amorphous solid dispersion (ASD) drug product? In this Perspective, the origin and significance of crystallinity within amorphous solid dispersions will be considered. Crystallinity can be found within an ASD from one of two pathways: (1) incomplete amorphization, or (2) crystal creation (nucleation and crystal growth). While nucleation and crystal growth is the more commonly considered pathway, where crystals originate as a physical stability failure upon accelerated or prolonged storage, manufacturing-based origins of crystallinity are possible as well. Detecting trace levels of crystallinity is a significant analytical challenge, and orthogonal methods should be employed to develop a holistic assessment of sample properties. Probing the impact of crystallinity on release performance which may translate to meaningful clinical significance is inherently challenging, requiring optimization of dissolution test variables to address the complexity of ASD formulations, in terms of drug physicochemical properties (e.g., crystallization tendency), level of crystallinity, crystal reference material selection, and formulation characteristics. The complexity of risk presented by crystallinity to product performance will be illuminated through several case studies, highlighting that a one-size-fits-all approach cannot be used to set specification limits, as the risk of crystallinity can vary widely based on a multitude of factors. Risk assessment considerations surrounding drug physicochemical properties, formulation fundamentals, physical stability, dissolution, and crystal micromeritic properties will be discussed.
Collapse
Affiliation(s)
- Dana E Moseson
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
- Worldwide Research and Development Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Lynne S Taylor
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
| |
Collapse
|
9
|
Larfors G, Andersson P, Jesson G, Liljebris C, Brisander M, Lennernäs H, Stenke L. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions. Eur J Haematol 2023; 111:644-654. [PMID: 37503797 DOI: 10.1111/ejh.14059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 07/29/2023]
Abstract
BACKGROUND Dasatinib and other tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML). However, as a lipophilic weak base, crystalline monohydrate, dasatinib (Sprycel®) is poorly soluble, rendering a pH-dependent absorption and a highly variable bioavailability. Thus, co-medication with proton pump inhibitors (PPI) profoundly impairs dasatinib uptake and is clearly recommended against. XS004 is a novel oral immediate release and amorphous solid dispersion (ASD) formulation of dasatinib and is bioequivalent to the original crystalline dasatinib at 30% lower dosages. XS004 is designed to mitigate gastric pH dependency, thus optimizing absorption and bioavailability. METHODS We investigated the prevalence of dasatinib and PPI co-medication among chronic-phase CML patients in a real-world setting and assessed the plasma pharmacokinetics (PK) of XS004 with and without PPI co-medication (omeprazole) in healthy volunteers. RESULTS Using the Swedish CML and Prescribed Drug Registers, we identified 676 TKI-treated CML patients; 320 (47%) had been prescribed PPI at some point after CML diagnosis. Among dasatinib-treated patients, the 2-year cumulative PPI co-medication was 24%. Interestingly, the 5-year overall survival was significantly lower for TKI-treated CML patients with versus without PPI co-medication (79% vs. 94%; hazard ratio 3.5; 95% confidence interval, 2.1-5.3; p < .0001). When assessing PK of XS004, neither Cmax nor area under the plasma concentration curve levels in plasma were significantly altered by the PPI co-medication. CONCLUSION In conclusion, despite warnings, PPI co-medication is common among dasatinib-treated CML patients in a real-world setting. The new XS004 ASD formulation of dasatinib provided, in contrast to original crystalline dasatinib, superior pH independence with stable bioavailability, thereby minimizing drug-drug interactions. This may improve the long-term efficacy and tolerability of dasatinib in CML.
Collapse
Affiliation(s)
- Gunnar Larfors
- Unit of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | | | | | | | | | - Hans Lennernäs
- Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden
| | - Leif Stenke
- Karolinska University Hospital and Karolinska Institutet, Department of Hematology, Theme Cancer and Department of Medicine Solna, Stockholm, Sweden
| |
Collapse
|
10
|
van Haaren C, De Bock M, Kazarian SG. Advances in ATR-FTIR Spectroscopic Imaging for the Analysis of Tablet Dissolution and Drug Release. Molecules 2023; 28:4705. [PMID: 37375260 DOI: 10.3390/molecules28124705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 06/06/2023] [Accepted: 06/09/2023] [Indexed: 06/29/2023] Open
Abstract
One of the major challenges in the development of effective pharmaceutical formulations for oral administration is the poor solubility of active pharmaceutical ingredients. For this reason, the dissolution process and drug release from solid oral dosage forms, such as tablets, is usually thoroughly studied in order to understand the dissolution behaviour under various conditions and optimize the formulation accordingly. Standard dissolution tests used in the pharmaceutical industry provide information on the amount of drug released over time; however, these do not allow for a detailed analysis of the underlying chemical and physical mechanisms of tablet dissolution. FTIR spectroscopic imaging, by contrast, does offer the ability to study these processes with high spatial and chemical specificity. As such, the method allows us to see the chemical and physical processes which occur inside the tablet as it dissolves. In this review, the power of ATR-FTIR spectroscopic imaging is demonstrated by presenting a number of successful applications of this chemical imaging technique to dissolution and drug release studies for a range of different pharmaceutical formulations and study conditions. Understanding these processes is essential for the development of effective oral dosage forms and optimization of pharmaceutical formulations.
Collapse
Affiliation(s)
- Céline van Haaren
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK
| | - Marieke De Bock
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK
| | - Sergei G Kazarian
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK
| |
Collapse
|